摘要
目的探讨AMACR、p63、34βE12在前列腺病变组织中的表达及其在鉴别诊断中的意义。方法应用免疫组织化学SP法检测37例前列腺腺癌、14例前列腺重度上皮内瘤变(HGPIN)、25例前列腺结节性增生(BPH)组织中AMACR、p63、34βE12的表达。结果AMACR在前列腺腺癌组织中阳性率为100.00%,表现为癌细胞弥漫性胞质内着色较深的颗粒状物,在HGPIN及BPH组织中阳性率分别为64.29%和0。AMACR在前列腺癌、HGPIN、BPH3组中的表达阳性率相互比较,均具有非常显著性差异(P<0.01)。p63、34βE12在前列腺癌、HGPIN、BPH中阳性率分别为0,71.43%和100.00%,3组阳性率相互比较,均具有非常显著性差异(P<0.01)。结论AMACR是前列腺癌诊断较为敏感的特异性标志物。联合标记AMACR、p63与34βE12在前列腺病变的鉴别断中具有重要意义。
Objective To investigate the expression of AMACR, p63 and 34βE12 in prostate disease and the significance in the diagnosis of the disease. Methods Immunohistochemistry was used to detect the expression of AMACR, p63 and 34βE12 in 37 cases of prostate adenocarcinoma, 14 cases of hlgh-grade prostatic intraepithelial neoplasia （HGPIN） and 25 cases of benign prostate hyperplasia（BPH）. Results The positive rate of AMACR was 100.0% in prostate adenocarcinoma tissues, with strong cytoplasmic granular staining and the positive rates of AMACR in HGPIN and BPH tissues were 64.29% and 0, respectively. The expression of AMACR was significantly different between the prostate adenocarcinoma, HGPIN and BPH （P 〈 0.01）. The positive rates of p63 and 34βE12 in prostate adenocarcinoma, HGPIN and BPH were 0, 71.43 % and 100.00%, respectively. There were significant differences of these values between three groups （P 〈 0.01）. Conclusion AMACR is a sensitive and specific marker for prostate adenocarcinomam and immunohistochemistry study using a combination of AMACR, p63 and 34βE12 may be of greater benefit in aiding the differential diagnoses of prostatic disease.
出处
《实用癌症杂志》
2006年第5期490-492,共3页
The Practical Journal of Cancer
